8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
May 4, 2026·SEC
Material company update
Feb 11, 2026·SEC
Inspire Medical Systems, Inc.(INSP)Earnings, Financials & Key Ratios
INSP•NYSE
8.7× P/E·Price updated Jun 19, 2026
AboutInspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. It also develops a novel, a closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.Show more
- Revenue$912M+13.6%
- EBITDA$65M+52.3%
- Net Income$145M+171.8%
- EPS (Diluted)4.89+179.4%
- Gross Margin85.39%+0.8%
- EBITDA Margin7.12%+34.0%
- Operating Margin5.59%+24.3%
- Net Margin15.95%+139.2%
- ROE19.77%+133.2%
INSP Key Insights
Inspire Medical Systems, Inc. (INSP) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Strong Piotroski F-Score: 7/9
- ✓Strong 5Y sales CAGR of 51.2%
- ✓Share count reduced 2.6% through buybacks
- ✓Efficient asset utilization: 1.0x turnover
✗Weaknesses
- ✗Weak momentum: RS Rating 10 (bottom 10%)
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when INSP posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
INSP Price & Volume
Inspire Medical Systems, Inc. (INSP) stock price & volume — 10-year historical chart
Loading chart...
INSP Growth Metrics
Inspire Medical Systems, Inc. (INSP) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years51.21%
3 Years30.77%
TTM8.94%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM97.18%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM107.04%
Return on Capital
10 Years-51.99%
5 Years-4.65%
3 Years1.61%
Last Year6.66%
INSP Recent Earnings
Inspire Medical Systems, Inc. (INSP) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 12/12 qtrs (100%)●Beat Revenue 8/12 qtrs (67%)
Q2 2026Latest
May 4, 2026Metric
Actual
Est
EPS
$0.10+136.3%
$0.28
Rev
$205M+2.3%
$200M
Q1 2026
Feb 11, 2026Metric
Actual
Est
EPS
$1.65+139.1%
$0.69
Rev
$269M+1.3%
$266M
Q4 2025
Nov 3, 2025Metric
Actual
Est
EPS
$0.38+353.3%
$0.15
Rev
$225M-14.4%
$262M
Q3 2025
Aug 4, 2025Metric
Actual
Est
EPS
$0.45+104.5%
$0.22
Rev
$217M+1.2%
$214M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 4, 2026 | $0.10vs $0.28+136.3% | $205Mvs $200M+2.3% |
| Q1 2026 | Feb 11, 2026 | $1.65vs $0.69+139.1% | $269Mvs $266M+1.3% |
| Q4 2025 | Nov 3, 2025 | $0.38vs $0.15+353.3% | $225Mvs $262M-14.4% |
| Q3 2025 | Aug 4, 2025 | $0.45vs $0.22+104.5% | $217Mvs $214M+1.2% |
Based on last 12 quarters of dataView full earnings history →
INSP Peer Comparison
Inspire Medical Systems, Inc. (INSP) competitors in Respiratory and sleep therapy devices — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NVCR | 1.62B | 14.28 | -11.70 | 8.28% | -25.66% | -50.82% | 0.85 | |
 TNDM | 1.05B | 15.30 | -5.03 | 7.93% | -9.2% | -68.29% | 2.86 | |
 IRTC | 3.44B | 104.65 | -75.29 | 26.24% | -3.53% | -20.6% | 4.79 | |
 MDT | 101.86B | 79.34 | 21.98 | 3.62% | 13% | 9.49% | 0.59 | |
 ABT | 153.68B | 88.38 | 11.57 | 4.59% | 31.88% | 27.26% | 0.32 | |
 BSX | 67.31B | 45.29 | 23.35 | 19.87% | 14.4% | 12.4% | 0.51 | |
 LVS | 32.33B | 48.72 | 20.73 | 15.22% | 13.41% | 95.8% | 8.34 | |
 RGEN | 7.45B | 132.02 | 153.51 | 16.36% | 6.73% | 2.46% | 0.33 |
Compare INSP vs Peers
Inspire Medical Systems, Inc. (INSP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
INSP Income Statement
Inspire Medical Systems, Inc. (INSP) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 28.57M | 50.59M | 82.05M | 115.38M | 233.39M | 407.86M | 624.8M | 802.8M | 911.98M | 915.25M |
Revenue Growth % | 73.9% | 77.1% | 62.18% | 40.62% | 102.28% | 74.75% | 53.19% | 28.49% | 13.6% | 8.94% |
Cost of Goods Sold | 6.02M | 10.06M | 13.64M | 17.62M | 33.28M | 66.11M | 96.58M | 122.99M | 133.22M | 130.19M |
COGS % of Revenue | 21.07% | 19.88% | 16.63% | 15.27% | 14.26% | 16.21% | 15.46% | 15.32% | 14.61% | - |
Gross Profit | 22.55M▲ 0% | 40.54M▲ 79.8% | 68.41M▲ 68.8% | 97.76M▲ 42.9% | 200.12M▲ 104.7% | 341.74M▲ 70.8% | 528.22M▲ 54.6% | 679.82M▲ 28.7% | 778.76M▲ 14.6% | 785.06M▲ 0% |
Gross Margin % | 78.93% | 80.12% | 83.37% | 84.73% | 85.74% | 83.79% | 84.54% | 84.68% | 85.39% | 85.78% |
Gross Profit Growth % | 80.08% | 79.77% | 68.75% | 42.91% | 104.7% | 70.77% | 54.57% | 28.7% | 14.55% | - |
Operating Expenses | 38.55M | 60.91M | 103.3M | 153.97M | 239.97M | 389.33M | 568.49M | 643.74M | 727.8M | 733.74M |
OpEx % of Revenue | 134.95% | 120.4% | 125.9% | 133.44% | 102.82% | 95.46% | 90.99% | 80.19% | 79.8% | - |
Selling, General & Admin | 32.36M | 53.53M | 90.47M | 127.87M | 202.62M | 320.69M | 451.96M | 529.61M | 624.64M | 632.55M |
SG&A % of Revenue | 113.27% | 105.8% | 110.26% | 110.83% | 86.81% | 78.63% | 72.34% | 65.97% | 68.49% | - |
Research & Development | 6.19M | 7.39M | 12.84M | 26.09M | 37.35M | 68.64M | 116.54M | 114.13M | 103.17M | 101.19M |
R&D % of Revenue | 21.68% | 14.6% | 15.65% | 22.61% | 16% | 16.83% | 18.65% | 14.22% | 11.31% | - |
Other Operating Expenses | 42K | -16K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Operating Income | -16M▲ 0% | -20.38M▼ 27.3% | -34.9M▼ 71.2% | -56.21M▼ 61.1% | -39.85M▲ 29.1% | -47.59M▼ 19.4% | -40.27M▲ 15.4% | 36.08M▲ 189.6% | 50.95M▲ 41.2% | 51.32M▲ 0% |
Operating Margin % | -56.02% | -40.28% | -42.53% | -48.72% | -17.07% | -11.67% | -6.45% | 4.49% | 5.59% | 5.61% |
Operating Income Growth % | 7.25% | -27.34% | -71.25% | -61.07% | 29.1% | -19.43% | 15.38% | 189.6% | 41.21% | - |
EBITDA | -15.72M | -19.98M | -34.4M | -55.37M | -38.63M | -45.73M | -37.42M | 42.63M | 64.91M | 62.23M |
EBITDA Margin % | -55.02% | -39.5% | -41.93% | -47.99% | -16.55% | -11.21% | -5.99% | 5.31% | 7.12% | 6.8% |
EBITDA Growth % | 8.35% | -27.15% | -72.14% | -60.94% | 30.23% | -18.38% | 18.17% | 213.92% | 52.26% | 6.25% |
D&A (Non-Cash Add-back) | 285K | 393K | 495K | 840K | 1.22M | 1.86M | 2.85M | 6.55M | 13.96M | 10.91M |
EBIT | -15.76M | -18.52M | -31.08M | -54.97M | -39.84M | -42.59M | -19.91M | 58.48M | 50.95M | 57.34M |
Net Interest Income | -1.55M | -1.43M | 1.68M | -1.02M | -2M | 3.37M | 20.56M | 23.23M | 17.4M | 12.33M |
Interest Income | 203K | 1.87M | 3.8M | 1.09M | 125K | 5.05M | 20.56M | 23.25M | 17.54M | 12.47M |
Interest Expense | 1.75M | 3.3M | 2.12M | 2.12M | 2.13M | 1.68M | 0 | 22K | 137K | 137K |
Other Income/Expense | -1.51M | -1.45M | 1.69M | -880K | -2.12M | 3.32M | 20.36M | 22.37M | 14.74M | 12.61M |
Pretax Income | -17.51M▲ 0% | -21.83M▼ 24.7% | -33.2M▼ 52.1% | -57.09M▼ 71.9% | -41.97M▲ 26.5% | -44.27M▼ 5.5% | -19.91M▲ 55.0% | 58.45M▲ 393.6% | 65.7M▲ 12.4% | 63.94M▲ 0% |
Pretax Margin % | -61.3% | -43.14% | -40.47% | -49.48% | -17.98% | -10.85% | -3.19% | 7.28% | 7.2% | 6.99% |
Income Tax | 0 | 0 | 40K | 115K | 72K | 613K | 1.25M | 4.94M | -79.72M | -67.2M |
Effective Tax Rate % | 0% | 0% | -0.12% | -0.2% | -0.17% | -1.38% | -6.26% | 8.46% | -121.35% | -105.11% |
Net Income | -17.51M▲ 0% | -21.83M▼ 24.7% | -33.24M▼ 52.3% | -57.2M▼ 72.1% | -42.04M▲ 26.5% | -44.88M▼ 6.8% | -21.15M▲ 52.9% | 53.51M▲ 353.0% | 145.42M▲ 171.8% | 131.14M▲ 0% |
Net Margin % | -61.3% | -43.14% | -40.52% | -49.58% | -18.01% | -11% | -3.39% | 6.67% | 15.95% | 14.33% |
Net Income Growth % | 5.49% | -24.65% | -52.3% | -72.08% | 26.5% | -6.75% | 52.87% | 352.96% | 171.77% | 97.18% |
Net Income (Continuing) | -17.51M | -21.83M | -33.24M | -57.2M | -42.04M | -44.88M | -21.15M | 53.51M | 145.42M | 131.14M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -1.30▲ 0% | -1.50▼ 15.4% | -1.40▲ 6.7% | -2.19▼ 56.4% | -1.54▲ 29.7% | -1.60▼ 3.9% | -0.72▲ 55.0% | 1.75▲ 343.1% | 4.89▲ 179.4% | 4.57▲ 0% |
EPS Growth % | 12.75% | -15.38% | 6.67% | -56.43% | 29.68% | -3.9% | 55% | 343.06% | 179.43% | 107.04% |
EPS (Basic) | -1.30 | -1.50 | -1.40 | -2.19 | -1.54 | -1.60 | -0.72 | 1.80 | 4.95 | - |
Diluted Shares Outstanding | 13.49M | 14.58M | 23.8M | 26.07M | 27.26M | 28.07M | 29.3M | 30.54M | 29.76M | 28.7M |
Basic Shares Outstanding | 13.49M | 14.58M | 23.8M | 26.07M | 27.26M | 28.07M | 29.3M | 29.76M | 29.37M | 28.7M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
INSP Balance Sheet
Inspire Medical Systems, Inc. (INSP) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 24.1M | 199.28M | 170.64M | 269.87M | 268.54M | 530.03M | 593.74M | 630.81M | 583.65M | 566.82M |
Cash & Short-Term Investments | 16.14M | 188.21M | 149.47M | 234.36M | 214.47M | 451.41M | 460.38M | 445.55M | 308.27M | 98.93M |
Cash Only | 8.96M | 97.29M | 22.86M | 190.52M | 214.47M | 441.59M | 185.54M | 150.15M | 104.81M | 98.93M |
Short-Term Investments | 7.19M | 90.92M | 126.61M | 43.84M | 0 | 9.82M | 274.84M | 295.4M | 203.46M | 0 |
Accounts Receivable | 3.86M | 6.67M | 13.13M | 25.06M | 34.18M | 61.23M | 89.88M | 93.07M | 119.69M | 105.09M |
Days Sales Outstanding | 49.29 | 48.1 | 58.41 | 79.29 | 53.45 | 54.79 | 52.51 | 42.31 | 47.9 | 46.9 |
Inventory | 3.67M | 2.67M | 5.83M | 8.48M | 17.23M | 11.89M | 33.88M | 80.12M | 145.29M | 166.24M |
Days Inventory Outstanding | 222.59 | 96.8 | 156.08 | 175.61 | 188.99 | 65.62 | 128.07 | 237.78 | 398.06 | 402.98 |
Other Current Assets | 426K | 1.73M | 0 | 0 | 0 | 5.5M | 9.6M | 12.07M | 10.4M | 196.56M |
Total Non-Current Assets | 994K | 802K | 10.62M | 11.32M | 26.55M | 34.84M | 83.07M | 177.58M | 323.67M | 344.56M |
Property, Plant & Equipment | 994K | 802K | 3.96M | 11.12M | 16.41M | 24.13M | 62.65M | 95.24M | 121.4M | 123.76M |
Fixed Asset Turnover | 28.74x | 63.08x | 20.72x | 10.38x | 14.23x | 16.90x | 9.97x | 8.43x | 7.51x | 7.78x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 6.28M | 0 | 9.94M | 0 | 9.14M | 71M | 96.33M | 426.8M |
Other Non-Current Assets | 0 | 0 | 381K | 204K | 204K | 10.71M | 11.28M | 11.34M | 6.09M | 17.25M |
Total Assets | 25.09M▲ 0% | 200.08M▲ 697.4% | 181.25M▼ 9.4% | 281.19M▲ 55.1% | 295.08M▲ 4.9% | 564.88M▲ 91.4% | 676.81M▲ 19.8% | 808.38M▲ 19.4% | 907.32M▲ 12.2% | 911.38M▲ 0% |
Asset Turnover | 1.14x | 0.25x | 0.45x | 0.41x | 0.79x | 0.72x | 0.92x | 0.99x | 1.01x | 1.06x |
Asset Growth % | 91.3% | 697.42% | -9.41% | 55.14% | 4.94% | 91.43% | 19.82% | 19.44% | 12.24% | 49.91% |
Total Current Liabilities | 7.15M | 11.15M | 16.86M | 20.73M | 41.31M | 61.19M | 78.11M | 88.5M | 96.06M | 89.42M |
Accounts Payable | 3M | 3.43M | 4.46M | 7.21M | 11.66M | 26.85M | 38.84M | 38.69M | 36.56M | 41.85M |
Days Payables Outstanding | 181.83 | 124.46 | 119.29 | 149.31 | 127.94 | 148.21 | 146.79 | 114.82 | 100.18 | 133.75 |
Short-Term Debt | 0 | 0 | 0 | 0 | 9.19M | 0 | 0 | 0 | 0 | 0 |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 555K | 1.24M | 0 | 0 | 0 | 0 | 0 | 0 | 8.41M | 47.57M |
Current Ratio | 3.37x | 17.86x | 10.12x | 13.02x | 6.50x | 8.66x | 7.60x | 7.13x | 6.08x | 6.34x |
Quick Ratio | 2.86x | 17.63x | 9.78x | 12.61x | 6.08x | 8.47x | 7.17x | 6.22x | 4.56x | 4.48x |
Cash Conversion Cycle | 90.05 | 20.44 | 95.2 | 105.59 | 114.5 | -27.8 | 33.79 | 165.27 | 345.79 | 316.14 |
Total Non-Current Liabilities | 16.62M | 24.93M | 24.56M | 30.72M | 24.73M | 7.68M | 26.19M | 30.19M | 30.1M | 29.62M |
Long-Term Debt | 16.46M | 24.93M | 24.52M | 24.75M | 15.8M | 7.54M | 0 | 0 | 0 | 29.55M |
Capital Lease Obligations | 0 | 0 | 0 | 5.89M | 8.8M | 7.54M | 24.85M | 30.04M | 30M | 91.21M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11.18M |
Other Non-Current Liabilities | 157K | 0 | 40K | 85K | 134K | -7.39M | 1.35M | 148K | 104K | 66K |
Total Liabilities | 23.61M | 36.08M | 41.42M | 51.44M | 66.04M | 68.87M | 104.3M | 118.69M | 126.16M | 119.04M |
Total Debt | 16.46M | 24.93M | 25.35M | 30.63M | 34.09M | 16.41M | 24.85M | 31.79M | 32.16M | 29.55M |
Net Debt | 7.5M | -72.36M | 2.49M | -159.89M | -180.37M | -425.18M | -160.69M | -118.36M | -72.66M | -69.38M |
Debt / Equity | 11.09x | 0.15x | 0.18x | 0.13x | 0.15x | 0.03x | 0.04x | 0.05x | 0.04x | 0.04x |
Debt / EBITDA | - | - | - | - | - | - | - | 0.75x | 0.50x | 0.47x |
Net Debt / EBITDA | - | - | - | - | - | - | - | -2.78x | -1.12x | -1.11x |
Interest Coverage | -8.99x | -5.61x | -14.67x | -25.97x | -18.72x | -25.40x | - | 2657.95x | 371.93x | 418.58x |
Total Equity | 1.48M▲ 0% | 164M▲ 10951.1% | 139.84M▼ 14.7% | 229.75M▲ 64.3% | 229.05M▼ 0.3% | 496.01M▲ 116.6% | 572.51M▲ 15.4% | 689.7M▲ 20.5% | 781.16M▲ 13.3% | 792.34M▲ 0% |
Equity Growth % | 122.46% | 10951.15% | -14.73% | 64.3% | -0.3% | 116.55% | 15.42% | 20.47% | 13.26% | 39.8% |
Book Value per Share | 0.11 | 11.25 | 5.87 | 8.81 | 8.40 | 17.67 | 19.54 | 22.58 | 26.25 | 27.61 |
Total Shareholders' Equity | 1.48M | 164M | 139.84M | 229.75M | 229.05M | 496.01M | 572.51M | 689.7M | 781.16M | 792.34M |
Common Stock | 13K | 23K | 24K | 27K | 27K | 29K | 30K | 30K | 29K | 29K |
Retained Earnings | -125.08M | -146.91M | -180.16M | -237.35M | -279.39M | -324.27M | -345.42M | -291.91M | -146.49M | -157.79M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | -52K | 102K | 29K | -55K | -86K | 800K | 536K | 464K | -352K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
INSP Cash Flow Statement
Inspire Medical Systems, Inc. (INSP) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -15.79M | -18.69M | -33.38M | -53.05M | -20.12M | 11.57M | 24.65M | 130.25M | 116.98M | 136.53M |
Operating CF Margin % | -55.28% | -36.95% | -40.68% | -45.97% | -8.62% | 2.84% | 3.95% | 16.22% | 12.83% | - |
Operating CF Growth % | 12.02% | -18.38% | -78.54% | -58.93% | 62.07% | 157.5% | 113.1% | 428.32% | -10.19% | 3839.63% |
Net Income | -17.51M | -21.83M | -33.24M | -57.2M | -42.04M | -44.88M | -21.15M | 53.51M | 145.42M | 131.14M |
Depreciation & Amortization | 285K | 393K | 1.4M | 840K | 1.99M | 2.9M | 2.85M | 6.55M | 13.96M | 16.02M |
Stock-Based Compensation | 243K | 1.22M | 0 | 12.82M | 0 | 0 | 82.47M | 116.01M | 0 | 129.93M |
Deferred Taxes | 100K | -53K | 0 | -22K | 0 | 0 | 0 | 0 | -88.75M | 1.01M |
Other Non-Cash Items | 315K | 714K | 5.04M | 1.4M | 26.79M | 51.74M | 1.27M | -7.51M | 133.73M | -84.48M |
Working Capital Changes | 777K | 861K | -6.57M | -10.88M | -6.86M | 1.81M | -40.78M | -37.71M | -87.38M | -57.08M |
Change in Receivables | -1.77M | -2.84M | -6.48M | -11.84M | -9.24M | -27.02M | -30.22M | -2.6M | -26.23M | -12.21M |
Change in Inventory | -315K | 1M | -3.17M | -2.65M | -8.75M | 5.34M | -22M | -46.23M | -65.17M | -66.51M |
Change in Payables | 1.82M | 439K | 1.03M | 2.05M | 4.78M | 14.36M | 9.3M | 604K | -3.75M | 12.9M |
Cash from Investing | -7.6M | -83.39M | -43.56M | 86.63M | 29.14M | -19.6M | -294.82M | -113.12M | 21.45M | 11.75M |
Capital Expenditures | -412K | -250K | -2.74M | -2.46M | -4.67M | -9.1M | -23.63M | -39.12M | -38.5M | -39.82M |
CapEx % of Revenue | 1.44% | 0.49% | 3.34% | 2.13% | 2% | 2.23% | 3.78% | 4.87% | 4.22% | 4.35% |
Acquisitions | 0 | 0 | 0 | -89.08M | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -7.19M | -83.14M | 0 | 89.08M | 0 | -10.5M | 0 | 0 | 0 | 0 |
Cash from Financing | 25.66M | 190.38M | 2.5M | 134.06M | 14.95M | 235.08M | 13.95M | -52.39M | -183.45M | -103.17M |
Debt Issued (Net) | 458K | 8M | 0 | 0 | 0 | -24.5M | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 25.2M | 182.38M | 2.5M | 134.06M | 14.95M | 259.62M | 31.11M | -47.23M | -160.41M | -91.73M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -75M | -175.02M | -100.01M |
Other Financing | 0 | 0 | 0 | 0 | 0 | -43K | -17.16M | -5.17M | -23.04M | -11.44M |
Net Change in Cash | 2.27M▲ 0% | 88.33M▲ 3791.3% | -74.43M▼ 184.3% | 167.66M▲ 325.3% | 23.95M▼ 85.7% | 227.13M▲ 848.4% | -256.06M▼ 212.7% | -35.39M▲ 86.2% | -45.34M▼ 28.1% | 45.05M▲ 0% |
Free Cash Flow | -16.2M▲ 0% | -18.94M▼ 16.9% | -35.59M▼ 87.8% | -55.5M▼ 56.0% | -24.79M▲ 55.3% | 2.47M▲ 110.0% | 1.02M▼ 58.6% | 91.12M▲ 8798.7% | 78.48M▼ 13.9% | 96.71M▲ 0% |
FCF Margin % | -56.72% | -37.44% | -43.37% | -48.1% | -10.62% | 0.61% | 0.16% | 11.35% | 8.61% | 10.57% |
FCF Growth % | 11.24% | -16.92% | -87.84% | -55.96% | 55.34% | 109.98% | -58.59% | 8798.73% | -13.88% | 22.65% |
FCF per Share | -1.20 | -1.30 | -1.49 | -2.13 | -0.91 | 0.09 | 0.03 | 2.98 | 2.64 | 3.37 |
FCF Conversion (FCF/Net Income) | 0.90x | 0.86x | 1.00x | 0.93x | 0.48x | -0.26x | -1.17x | 2.43x | 0.80x | 0.74x |
Interest Paid | 0 | 0 | 2.03M | 0 | 1.89M | 2.32M | 0 | 22K | 0 | 133K |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
INSP Key Ratios
Inspire Medical Systems, Inc. (INSP) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -1179.99% | -26.38% | -21.88% | -30.96% | -18.33% | -12.38% | -3.96% | 8.48% | 19.77% | 17.98% |
Return on Invested Capital (ROIC) | -210.81% | -30.38% | -22.37% | -39.73% | -50.43% | -59.74% | -12.52% | 5.51% | 5.97% | 5.81% |
Gross Margin | 78.93% | 80.12% | 83.37% | 84.73% | 85.74% | 83.79% | 84.54% | 84.68% | 85.39% | 85.78% |
Net Margin | -61.3% | -43.14% | -40.52% | -49.58% | -18.01% | -11% | -3.39% | 6.67% | 15.95% | 14.33% |
Debt / Equity | 11.09x | 0.15x | 0.18x | 0.13x | 0.15x | 0.03x | 0.04x | 0.05x | 0.04x | 0.04x |
Interest Coverage | -8.99x | -5.61x | -14.67x | -25.97x | -18.72x | -25.40x | - | 2657.95x | 371.93x | 418.58x |
FCF Conversion | 0.90x | 0.86x | 1.00x | 0.93x | 0.48x | -0.26x | -1.17x | 2.43x | 0.80x | 0.74x |
Revenue Growth | 73.9% | 77.1% | 62.18% | 40.62% | 102.28% | 74.75% | 53.19% | 28.49% | 13.6% | 8.94% |
Related:INSP Dividend History·INSP Revenue History·INSP Price History·INSP P/E History·INSP Financial Ratios·INSP Institutional Holders
INSP SEC Filings & Documents
Inspire Medical Systems, Inc. (INSP) SEC filings — annual & quarterly reports (10-K, 10-Q)
INSP Frequently Asked Questions
Inspire Medical Systems, Inc. (INSP) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Inspire Medical Systems, Inc. (INSP) reported $915.2M in revenue for fiscal year 2025. This represents a 5472% increase from $16.4M in 2016.
Inspire Medical Systems, Inc. (INSP) grew revenue by 13.6% over the past year. This is steady growth.
Yes, Inspire Medical Systems, Inc. (INSP) is profitable, generating $131.1M in net income for fiscal year 2025 (15.9% net margin).
Dividend & Returns
Inspire Medical Systems, Inc. (INSP) has a return on equity (ROE) of 19.8%. This is reasonable for most industries.
Inspire Medical Systems, Inc. (INSP) generated $96.7M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.